🔍 Rechercher dans les archives
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
LEXINGTON, Mass. and AMSTERDAM, March 02, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformativ...
Why Is Aardvark Therapeutics Stock Sinking Monday?
Aardvark Therapeutics Inc. (NASDAQ:AARD) shares are down during Monday’s premarket session following the company’s announcement to voluntarily pau...
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflect...
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
MALVERN, Pa., March 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therap...
What's being built at an old downtown Phoenix medical office?
...
‘DTF St. Louis’ Episode 1 Recap: Love Will Tear Us Apart
Some people have a midlife crisis. Other people have a midlife crisis....
Partnering for health: No-cost clinic coordinates with mental health court, Springdale police, Restoring Hope
FAYETTEVILLE -- The judge who presides over Washington County's mental health court says a new partnership with a no-cost clinic is important because ...
Volunteers prepare 20,000 bouquets as hospice fundraiser begins Monday
The 40th annual Hospice Spring Bouquet Sale begins Monday, and nearly 20,000 bouquets are already packed and ready....
What to know about kratom as Utah eyes tighter restrictions
With Utah legislators proposing tighter restrictions on kratom products, Utah State University Extension health and wellness faculty member Ashley Yau...
Oral Care Market To Reach USD 95.7 Billion By 2036 At 5.1% CAGR Driven By Premiumisation And Retail Expansion
(MENAFN - EIN Presswire) EINPresswire/ -- The global oral care market is projected to expand from USD 58.2 billion in 2026 to USD 95.7 billion by 2036...
‘Cash me outside’ rapper announces setback in cancer treatment
The 22-year-old rapper first disclosed her cancer diagnosis in November 2024, explaining that her medicine caused weight loss that drew online critici...
InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China
BEIJING, March 01, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the...
Bill addresses doctor shortage
FRANKFORT, Ky. (KT) – In a bid to lessen Kentucky’s medical doctor shortage, a bill that rwhich passed the Senate Health Services Committee on Wed...
NCH receives $10M gift to boost cancer program for women
NCH will enable more patients to get local care...
The family of Henrietta Lacks settles a second lawsuit over cell use
The family of Henrietta Lacks, whose cells were taken without her consent as she battled cervical cancer, settled a lawsuit with Novartis....
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar ...
- Late breaking Poster Presentation at AAAAI -...
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of ...
SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as...
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of ...
SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as...
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in ...
– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p < 0.0001)in new analysiswith adjustment for concomitant rescue...
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of ...
SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as...